Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of C-CAR088 in relapsed or refractory multiple myeloma
CTR20221467Phase 2Active
- Sponsor
- Cellular Biomedicine Group
- Start
- Nov 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of trovocabtagene autoleucel in multiple myeloma (MM), sponsored by Cellular Biomedicine Group. Started Nov 2022; status: active.
02
Drugs
trovocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20221467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221467.